Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up

Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up

Introduction: Minimally invasive extracorporeal circulation (MiECC) reduced inflammatory burden, leading to best clinical outcomes in patients treated with coronary artery bypass grafting (CABG). Despite this, the patients with type 2 diabetes mellitus (T2DM) vs those without T2DM (non-T2DM) have a...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Celestino Sardu, Massimo Massetti, Nicola Testa, Luigi Di Martino, Gaetano Castellano, Fabrizio Turriziani, Ferdinando Carlo Sasso, Michele Torella, Marisa De Feo, Gaetano Santulli, Giuseppe Paolisso, Raffaele Marfella
Format: article
Langue:EN
Publié: Frontiers Media S.A. 2021
Sujets:
type 2 diabetes mellitus, coronary heart disease
coronary artery bypass grafting
sodium-glucose transporter 2 inhibitors
minimally invasive extracorporeal circulation
multi-vessel coronary stenosis
over-inflammation
Therapeutics. Pharmacology
RM1-950
Accès en ligne:https://doaj.org/article/f33bf0978d55443e8ab8cb98ecd53960
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/f33bf0978d55443e8ab8cb98ecd53960

Documents similaires